A5008963665- Health Systems, Economic Evaluations, Quality of Life
- Atrial Fibrillation Management and Outcomes
- Pharmaceutical Economics and Policy
- Venous Thromboembolism Diagnosis and Management
- Biosimilars and Bioanalytical Methods
- Acute Ischemic Stroke Management
- Economic and Environmental Valuation
- Retinal Diseases and Treatments
- Cardiac Arrhythmias and Treatments
- Retinal Imaging and Analysis
- Retinal and Optic Conditions
- Stroke Rehabilitation and Recovery
- Botulinum Toxin and Related Neurological Disorders
- Cerebral Palsy and Movement Disorders
- Peripheral Artery Disease Management
- Rheumatoid Arthritis Research and Therapies
- Intellectual Property and Patents
- Pharmaceutical studies and practices
- Inhalation and Respiratory Drug Delivery
- Neurological disorders and treatments
- Cerebrovascular and Carotid Artery Diseases
- Biotechnology and Related Fields
- Asthma and respiratory diseases
- Acute Myocardial Infarction Research
- Autoimmune and Inflammatory Disorders Research
Pharmacoeconomics and Health Outcomes Research Iberia (Spain)
2014-2021
To assess the cost-effectiveness of stent-retriever mechanical thrombectomy and intravenous tissue plasminogen activator compared with alone in patients acute ischaemic stroke due to large vessel occlusions Spain.Clinical data were taken from SWIFT PRIME clinical trial. A lifetime Markov state transition model defined by modified Rankin Scale score was developed estimate costs health outcomes (life years gained quality adjusted life years). Spanish National Health System perspective (direct...
Abstract Objective To assess the cost-effectiveness of tofacitinib-containing treatment sequences versus containing only standard biological therapies in patients with moderate-to-severe rheumatoid arthritis (RA) after failure conventional synthetic disease-modifying antirheumatic drugs (csDMARD-IR population) and previously treated methotrexate (MTX) who show an inadequate response to second-line therapy any tumour necrosis factor inhibitor (TNFi-IR population). Methods A patient-level...
Abstract Background Patient access to orphan medicinal products (OMPs) is limited and varies between countries, reimbursement decisions on OMPs are complex, there a need for more transparent processes know which criteria should be considered inform these decisions. This study aimed determine the most relevant of in Spain, from multi-stakeholder perspective, using multicriteria decision analysis (MCDA). Methods An MCDA was developed 3 phases included 28 stakeholders closely related field rare...
Abstract Background The DRCR.net Protocol T clinical trial assessed the comparative efficacy and safety of anti-VEGF treatments including aflibercept, ranibizumab bevacizumab in diabetic macular edema (DME). Post -hoc analyses showed that after a 12-week induction period, there was still DME resolution an increasing number patients through week 24. Purpose To assess cost consequences extending loading dose from 3 to 6 monthly injections with persistent Spain. Methods From hospital pharmacy...
Our objective was to assess the cost effectiveness of apixaban versus edoxaban in prevention stroke and systemic embolism (SE) patients with atrial fibrillation (AF) Spain.We customized a Markov model ten health states estimate lifetime economic clinical outcomes 6-week cycles. The efficacy (clinical event rates per 100 patient-years) safety data were derived from pairwise indirect treatment comparison. analysis conducted both national service (NHS) societal perspectives, included...
The clinical and economic management of retinal diseases has become more complex following the introduction new intravitreal treatments. Multicriteria decision analysis (MCDA) offers potential to overcome challenges associated with traditional decision-making tools. A MCDA determine most relevant criteria in diabetic macular edema (DME) based on perspectives multiple stakeholders Spain was developed. This termed MULTIDEX-EMD study. Nineteen (7 physicians, 4 pharmacists, 5 health authorities...
Estimar la relación coste-utilidad de seis meses tratamiento con apixaban (10 mg/12 h, siete primeros días; 5 h después) para el primer evento tromboembolismo venoso (TEV) y prevención recurrencias frente a dabigatrán (150 h) después cinco días heparina bajo peso molecular (HBPM/dabigatrán) rivaroxaban (15 los 21 20 mg/día). Se simuló un modelo Markov evolución enfermedad en 1.000 pacientes adultos lo largo su vida. La eficacia se obtuvo metanálisis, calculándose años vida ganados (AVG)...